Education and Training
A Pilot Trial of Adalimumab for the Treatment of Osteoarthritis
A 12 week trial of Adalimumab in subjects with active erosive inflammatory OA who have ahd an inadequate response to NSAID therapy
Stanford is currently not accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- drug: Adalimumab
Eligibility
Inclusion Criteria:
- Age 45 or older, >/=2 tender and 2 swollen joints, inadequate response to NSAID
therapy, hand radiographs with evidence of erosive changes, acceptable form of birth
control
Exclusion Criteria:
- Autoimmune arthropathy, History of psoriasis, Previous TNF therapy, current use of any
DMARD, evidence of TB, history of Hep C, B, or HIV
Ages Eligible for Study
45 Years - N/A
Genders Eligible for Study
All
Not currently accepting new patients for this trial
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Not Recruiting